Skip to Content
Merck Clinical Trials Logo

Clinical Trials

  • English
  • Español
Merck

Clinical Trials

Merck Clinical Trials Primary

  • About clinical trials
    • How does participation work?
    • What to consider
    • Frequently asked questions
  • Resources
    • For patients
    • For caregivers
  • Our medical science
  • For HCPs

Condition: Pancreatic Ductal Adenocarcinoma

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors

October 9, 2022

By clique_admin

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC),

Merck Clinical Trials Logo Merck Clinical Trials
  • Merck.com
  • Privacy Policy
  • Terms of Use
  • Policies & Perspectives
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

THIS WEBSITE IS INTENDED FOR A UNITED STATES AUDIENCE ONLY

Merck Essential Accessibility

Icon for accessibility